Literature DB >> 9547235

Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins.

Y Sun1, S Wu, G Bu, M K Onifade, S N Patel, M J LaDu, A M Fagan, D M Holtzman.   

Abstract

The epsilon4 allele of apolipoprotein E (apoE) is associated with increased risk for Alzheimer's disease (AD) and poor outcome after brain injury. In the CNS, apoE is expressed by glia, predominantly astrocytes. To define the potential biological functions of different human apoE isoforms produced within the brain, transgenic mice were generated in which human apoE3 and apoE4 expression is under control of the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter. These animals were then bred back to apoE knock-out mice. Human apoE protein is found within astrocytes and the neuropil throughout development and into the adult period, as assessed by immunocytochemistry and immunoblot analysis in several GFAP-apoE3 and E4 lines. Cultured astrocytes from these mice secrete apoE3 and apoE4 in lipoproteins that are high-density lipoprotein-like in size. When primary hippocampal neurons are grown in the presence of astrocyte monolayers derived from these transgenic mice, there is significantly greater neurite outgrowth from neurons grown in the presence of apoE3-secreting astrocytes compared with apoE4-secreting or apoE knock-out astrocytes. These effects are not dependent on direct astrocyte-neuron contact and appear to require the low-density lipoprotein receptor-related protein. These data suggest that astrocyte-secreted, apoE3-containing lipoproteins have different biological effects than apoE4-containing lipoproteins. In addition to providing information regarding the role of astrocyte-secreted apoE lipoproteins in the normal brain, these animals will also be useful in models of both AD and CNS injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9547235      PMCID: PMC6792658     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  75 in total

1.  Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma.

Authors:  A L Biere; B Ostaszewski; E R Stimson; B T Hyman; J E Maggio; D J Selkoe
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

2.  Human APOE protein localized in brains of transgenic mice.

Authors:  B H Bowman; F Yang; J M Buchanan; G S Adrian; A O Martinez; L Jansen; M Zhao; S L Atherton; J E Hixson
Journal:  Neurosci Lett       Date:  1996-11-15       Impact factor: 3.046

3.  ApoE genotype and survival from intracerebral haemorrhage.

Authors:  M J Alberts; C Graffagnino; C McClenny; D DeLong; W Strittmatter; A M Saunders; A D Roses
Journal:  Lancet       Date:  1995-08-26       Impact factor: 79.321

Review 4.  Alzheimer's disease: a central role for amyloid.

Authors:  D J Selkoe
Journal:  J Neuropathol Exp Neurol       Date:  1994-09       Impact factor: 3.685

5.  Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor.

Authors:  C R Gutman; W J Strittmatter; K H Weisgraber; W D Matthew
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

Review 6.  Human apolipoprotein E: the Alzheimer's disease connection.

Authors:  K H Weisgraber; R W Mahley
Journal:  FASEB J       Date:  1996-11       Impact factor: 5.191

7.  Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues.

Authors:  S K Moestrup; J Gliemann; G Pallesen
Journal:  Cell Tissue Res       Date:  1992-09       Impact factor: 5.249

8.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.

Authors:  K C Evans; E P Berger; C G Cho; K H Weisgraber; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Effects of apoprotein E on intracellular metabolism of model triglyceride-rich particles are distinct from effects on cell particle uptake.

Authors:  B Schwiegelshohn; J F Presley; M Gorecki; T Vogel; Y A Carpentier; F R Maxfield; R J Deckelbaum
Journal:  J Biol Chem       Date:  1995-01-27       Impact factor: 5.157

10.  Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system.

Authors:  J K Boyles; R E Pitas; E Wilson; R W Mahley; J M Taylor
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more
  62 in total

1.  Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.

Authors:  M Buttini; M Orth; S Bellosta; H Akeefe; R E Pitas; T Wyss-Coray; L Mucke; R W Mahley
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease.

Authors:  L N Nilsson; K R Bales; G DiCarlo; M N Gordon; D Morgan; S M Paul; H Potter
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

3.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

4.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

5.  Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation.

Authors:  M Zhuo; D M Holtzman; Y Li; H Osaka; J DeMaro; M Jacquin; G Bu
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

6.  Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice.

Authors:  I Tesseur; J Van Dorpe; K Spittaels; C Van den Haute; D Moechars; F Van Leuven
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

7.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

8.  Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele.

Authors:  Nicola Filippini; Bradley J MacIntosh; Morgan G Hough; Guy M Goodwin; Giovanni B Frisoni; Stephen M Smith; Paul M Matthews; Christian F Beckmann; Clare E Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

9.  Apolipoprotein E Regulates Injury-Induced Activation of Hippocampal Neural Stem and Progenitor Cells.

Authors:  Sue Hong; Patricia M Washington; Ahleum Kim; Cui-Ping Yang; Tzong-Shiue Yu; Steven G Kernie
Journal:  J Neurotrauma       Date:  2015-06-11       Impact factor: 5.269

10.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.